PDGFRA and hypereosinophilic syndrome: A phase 2 clinical trial for platelet-derived growth factor receptor alpha (PDGFRA)-negative hypereosinophilic syndrome (HES) has further demonstrated sustained clinical and laboratory responses, suggesting that benralizumab may offer therapeutic advantages in a broader range of eosinophilic conditions (10).